ZA200603542B - Oral formulations of desoxypeganine and uses thereof - Google Patents

Oral formulations of desoxypeganine and uses thereof

Info

Publication number
ZA200603542B
ZA200603542B ZA200603542A ZA200603542A ZA200603542B ZA 200603542 B ZA200603542 B ZA 200603542B ZA 200603542 A ZA200603542 A ZA 200603542A ZA 200603542 A ZA200603542 A ZA 200603542A ZA 200603542 B ZA200603542 B ZA 200603542B
Authority
ZA
South Africa
Prior art keywords
desoxypeganine
oral formulations
formulations
oral
Prior art date
Application number
ZA200603542A
Other languages
English (en)
Inventor
Moormann Joachim
Opitz Klaus
Hoffmann Hans-Rainer
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of ZA200603542B publication Critical patent/ZA200603542B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200603542A 2003-11-24 2006-05-05 Oral formulations of desoxypeganine and uses thereof ZA200603542B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10354894A DE10354894A1 (de) 2003-11-24 2003-11-24 Orale Formulierungen des Desoxypeganins und deren Anwendungen

Publications (1)

Publication Number Publication Date
ZA200603542B true ZA200603542B (en) 2007-02-28

Family

ID=34638177

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603542A ZA200603542B (en) 2003-11-24 2006-05-05 Oral formulations of desoxypeganine and uses thereof

Country Status (20)

Country Link
US (1) US20070155774A1 (es)
EP (1) EP1827402A1 (es)
JP (1) JP2007512270A (es)
KR (1) KR20060123194A (es)
CN (1) CN1886137A (es)
AR (1) AR046665A1 (es)
AU (1) AU2004294690B2 (es)
BR (1) BRPI0416415A (es)
CA (1) CA2546950A1 (es)
DE (1) DE10354894A1 (es)
EA (1) EA008945B1 (es)
IL (1) IL175746A0 (es)
MX (1) MXPA06005733A (es)
MY (1) MY141008A (es)
NO (1) NO20062668L (es)
NZ (1) NZ547282A (es)
TW (1) TW200526223A (es)
UA (1) UA87291C2 (es)
WO (1) WO2005053698A1 (es)
ZA (1) ZA200603542B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648421B1 (en) * 2003-07-24 2017-10-18 GlaxoSmithKline LLC Orally dissolving films
AU2007214474B2 (en) * 2006-02-17 2011-01-20 Novartis Ag Disintegrable oral films
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
EP2874824A1 (en) 2012-07-23 2015-05-27 Crayola LLC Dissolvable films and methods of using the same
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN142428B (es) * 1974-07-05 1977-07-09 Schering Ag
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
JPS6393717A (ja) * 1986-10-09 1988-04-25 Sekisui Chem Co Ltd 口腔粘膜用粘着剤もしくは接着剤
EP0386960A3 (en) * 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5312817A (en) * 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen

Also Published As

Publication number Publication date
WO2005053698A1 (de) 2005-06-16
EP1827402A1 (de) 2007-09-05
MXPA06005733A (es) 2006-08-17
CN1886137A (zh) 2006-12-27
DE10354894A1 (de) 2005-07-07
US20070155774A1 (en) 2007-07-05
EA008945B1 (ru) 2007-10-26
TW200526223A (en) 2005-08-16
AU2004294690A1 (en) 2005-06-16
AU2004294690B2 (en) 2010-04-08
AR046665A1 (es) 2005-12-14
MY141008A (en) 2010-02-12
EA200601015A1 (ru) 2006-10-27
NO20062668L (no) 2006-06-09
KR20060123194A (ko) 2006-12-01
CA2546950A1 (en) 2005-06-16
IL175746A0 (en) 2008-04-13
NZ547282A (en) 2009-10-30
UA87291C2 (ru) 2009-07-10
BRPI0416415A (pt) 2007-05-08
JP2007512270A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
HK1134023A1 (en) Oral and personal care compositions and methods
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1701691A4 (en) METHODS AND COMPOSITIONS FOR ORAL HYGIENE
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
PL1615622T3 (pl) Preparaty doksycyklin do jednorazowego dziennego podawania
EP1551376A4 (en) IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE
HK1079710A1 (zh) 口腔護理套件和組合物
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
AU2003267644A8 (en) Dental compositions and methods
EP1594544A4 (en) ORAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR THE APPLICATION THEREOF
AU2003299441A8 (en) Nf-hev compositions and methods of use
IL166337A0 (en) Oral administration of calctionin
IL175746A0 (en) Oral formulations of desoxypeganine and uses thereof
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
PL378269A1 (pl) Kompozycje do pielęgnacji jamy ustnej i sposoby
GB0202900D0 (en) Novel formulations of drugs
AU2003239868A8 (en) Sunscreen compositions and methods of use thereof
HK1090519A1 (en) Combinations of vasoprotective agents and formulations containing them
EP1625141A4 (en) GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF
GB0325383D0 (en) Oral formulations
EP1583557A4 (en) VACCINE COMPOSITIONS AND METHODS
AU2003294684A8 (en) Ketoprofen compositions and methods of making them
EP1534293A4 (en) INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION
EP1682088A4 (en) ORAL MICROEMULSION COMPOSITION COMPRISING BIPHENYLDIMETHYLDICARBOXYLATE AND SILYBINE
GB0327050D0 (en) Therapeutic methods compositions and uses